Author: admin

Sensor Market to Grow Exponentially with a Striking 8.10% CAGR through 2031 Innovations in Sensor Technologies to Drive the Market

“Skyquest Technology”
Sensor Market Size, Share, Growth Analysis, By Parameters Measured(Temperature, Pressure, Level, Flow), By Mode of Operation(Optical, Electrical Resistance, Biosensors, Piezoresistive), By End-User Industry(Automotive, Consumer Electronics (Smartphones, Tablets, Laptops), By Region – Industry Forecast 2024-2031

sensor market was valued at USD 204.31 billion in 2022 and is expected to rise from USD 220.86 billion in 2023 to reach a value of USD 411.83 billion by 2031, at a CAGR of 8.10% during the forecast period (2024–2031). 

Sensor market to show continuous growth in the coming years owing to the increasing penetration of digitalization. The growing demand of consumers is forcing quick production time, which ultimately demands smart sensors. Hence, rising demand for highly efficient devices supporting the need to address constraints in different applications to significantly impact the sensor market.

Sensors find applications in industries like aviation, marine, telecom, automotive, computer hardware, manufacturing, medical, and chemical. The sensors used in the aeronautics industry help measureaircraft navigation, controlling different instruments, and unique systems. Such data is used in incompetent flight operations to enhance the performance of design enhancements. In the medical industry, sensors-based signals in surgical devices instruments, and medical equipment are used to treat, diagnose, and to control function by healthcare physicians. In automotive, sensors are utilized in braking & traction control, airbags – anti cushion restraint system (ACRS), comfort and convenience, engine data, avoid collisions and more.

Download a detailed overview:

https://www.skyquestt.com/sample-request/sensor-market

Increasing Use of Sensors in Medical and Healthcare Systems to Noticeably Propel the Market

The improvements in sensor technology comprise progress in sensor development backed by improvements in miniaturization, material science, and data analytics. These developments offer unmatched prospects for different applications in biomedical and healthcare domains. Sensors are widely used to diagnose and prevent diseases by identifying vital biomarkers. Sensors also simplify health assessment by observing and studying physiological signs. Besides, sensors have a key role in healthcare and medical systems, by acting as key units for treatment and monitoring. Also, AI development is one major advancement that offers reasonable techniques for monitoring and allows usto understand personal healthcare and smart homes. Such AI sensors hold numerous competencies like performing human-like computation and identifying multi-dimensional information.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/sensor-market

  • In March 2022, Honeywell Incorporation introduced a novel accelerometer that offers reliability and high performance in a rugged, small, and low-price package. The MV60 (MEMS) micro-electro-mechanical system accelerometer is specially designed for use in aerospace & defense also holds possible applications in marine and industrial uses.
  • In April 2024, In the current industrial scenario, there is increased demand for sensors that can capably operate in challenging environments, are miniaturized, low power, wireless, and digital. To meet this increasing demand for improved data acquisition for better monitoring of condition, TE Connectivity is increasing IoT pressure sensor (wireless) offering.
  • In June 2024, Texas Instruments launched the pioneer 650V 3-phase GaN IPM for 250 Watts motor drive uses. The novel GaN IPM fulfils most of the performance and design challenges faced by engineers while manufacturing major HVAC systems and home appliances.
  • In June 2024, Infineon Technologies AG launched its 600 V CoolMOS™ S7TA Superjunction MOSFET for use in automotive power management. It is specially manufactured to fulfillthe needs of automotive electronic devices. Also, S7TA presents an incorporated temperature sensor that aims to improve the precision of junction temperature sensing.

 

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/sensor-market

The introduction of IoT transforming the use of sensors. IoT along with sensors is driving healthcare, the improvements that allow patients to control their health and offer doctors with essential tools for treatment and diagnosis. With more advances, the sensors are expected to hold more promises in future for greater accessibility, precision, personal care to patients, eventually contributing to better patient results and an efficient healthcare ecology.

Related Reports:

Blockchain Market

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/sensor-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sensor Market to Grow Exponentially with a Striking 8.10% CAGR through 2031 Innovations in Sensor Technologies to Drive the Market

The 3D Urology and Prostate Clinics Announces Launch of Revolutionary 3D Targeted Therapy for Prostate Treatment

The 3D Urology and Prostate Clinics is revolutionizing prostate treatment with its advanced 3D Targeted Therapy, providing a safe, effective, and non-invasive alternative for patients.

The 3D Urology and Prostate Clinics, a leader in men’s health and prostate care, is proud to announce the launch of its groundbreaking 3D Targeted Therapy. This innovative treatment method marks a significant advancement in prostate care, offering patients a minimally invasive and highly effective alternative to traditional treatment options.The 3D Urology and Prostate Clinics

3D Targeted Therapy utilizes sophisticated 3D imaging technology to precisely target and treat affected areas within the prostate gland. By focusing treatment on specific areas needing attention, surrounding healthy tissues are spared from unnecessary radiation, minimizing side effects and promoting faster recovery. This approach stands in stark contrast to traditional treatment methods like surgery or conventional radiation therapy, which often carry a higher risk of complications and side effects, such as erectile dysfunction and urinary incontinence. These traditional methods can also involve lengthy hospital stays and arduous recovery periods, significantly impacting a man’s quality of life.

The non-invasive nature of 3D prostate Targeted Treatment makes it a particularly attractive option for men seeking treatment with minimal disruption to their daily lives. This outpatient procedure eliminates the need for lengthy hospital stays and allows patients to resume their routines soon after treatment. Compared to traditional treatments, which can often result in extended recovery times and limit daily activities, 3D Targeted Therapy empowers men to maintain their lifestyles with minimal interruption. The clinic’s commitment to utilizing the latest technological advancements ensures patients receive the most effective and efficient care available.

The 3D Urology and Prostate Clinics understands that men have diverse needs and preferences when it comes to their health. The clinic is also home to the renowned 3D Urology Clinic, a specialized facility dedicated to providing comprehensive urological care using state-of-the-art technology and patient-centric treatment approaches. Patients at the 3D Urology Clinic benefit from a multidisciplinary team of specialists who provide individualized care tailored to each patient’s unique needs. From diagnosis to treatment and follow-up care, the clinic is dedicated to addressing every aspect of a patient’s journey with the utmost care and expertise.

The 3D Urology and Prostate Clinics prioritizes patient well-being through every step of the treatment process. The clinic promotes open communication between patients and medical professionals, fostering an environment of trust and mutual respect. The staff is dedicated to providing patients with the knowledge and resources necessary to make well-informed decisions about their prostate health in a comfortable and supportive environment. This patient-centric approach ensures that men feel empowered to actively participate in their treatment decisions and achieve the best possible outcomes.

About The 3D Urology and Prostate Clinics

The 3D Urology and Prostate Clinics is a leading healthcare provider specializing in men’s health, with a particular focus on providing advanced and compassionate care for various prostate conditions. The clinic is dedicated to utilizing cutting-edge technology, such as 3D Targeted Therapy, to deliver exceptional treatment outcomes and improve men’s lives.

Media Contact
Company Name: The 3D Urology and Prostate Clinics
Contact Person: Miss Alisa Wang
Email: Send Email
Phone: +86-18673216429 (WhatsApp)
State: Hunan Province
Country: China
Website: http://www.3dprostatecure.com

Leading Realtor Agent in South Jordan, UT Discusses Common Client Oversights in Real Estate Transactions

Hyrum Rosquist, a well-known Realtor agent in South Jordan, UT, addresses common mistakes that clients often make during real estate transactions. His insights aim to empower buyers and sellers to make informed decisions and optimize their outcomes in the competitive South Jordan market.

“Many clients trust the first real estate professional they meet, which can lead to oversight of crucial details,” says Rosquist. He emphasizes the importance of evaluating an agent’s experience and their track record of successful sales before making a commitment. This critical vetting can significantly influence the success of both buying and selling real estate ventures.

Rosquist also highlights the issue of not thoroughly understanding contracts. “It’s imperative that clients take the time to read and comprehend all contractual documents they are signing,” he advises. This oversight is common but can be mitigated through careful review and consultation with knowledgeable professionals. By doing so, clients can avoid potential pitfalls and ensure their interests are fully protected throughout the transaction.

In his role as a leading real estate selling agent in South Jordan, UT, Rosquist has built a reputation for his detailed approach to client education and transparency. He ensures that every client is well-informed about their rights and obligations, providing a foundation for successful and satisfying real estate transactions.

“Choosing the right agent is just as important as the property itself. Ensure your agent is not only knowledgeable but also prioritizes your best interests and guides you through the process with integrity,” Rosquist adds. His advice is backed by years of experience as a real estate agent in South Jordan, UT, and a deep understanding of the market dynamics.

For those in need of expert guidance and a trustworthy partnership in real estate, Hyrum Rosquist offers his expertise. Visit Hyrum Rosquist’s website at http://hyrumrosquist.kw.com/ to learn more about how you can benefit from working with a dedicated Realtor in South Jordan, UT.

Media Contact
Company Name: Rosquist Real Estate | Real Estate Agent in South Jordan UT
Contact Person: Hyrum Rosquist
Email: Send Email
Phone: +1 801-618-6869
Address:4020 W Daybreak Pkwy
City: South Jordan
State: Utah 84095
Country: United States
Website: http://southjordanrealtor.kw.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leading Realtor Agent in South Jordan, UT Discusses Common Client Oversights in Real Estate Transactions

Best Real Estate Agent in Los Altos, CA, Leverages Local Expertise for Strategic Home Sales

Shelly Potvin, a highly esteemed real estate agent in Los Altos, CA, celebrates 26 years of leveraging her local expertise to achieve strategic home sales. Potvin’s extensive experience and deep connections in the community have established her as a leading figure among Los Altos, CA Realtors.

Having lived in Los Altos for 36 years, Potvin possesses unparalleled knowledge of the local market. Her career in real estate was sparked in 1999 after she was inspired by a well-known Realtor and a real estate licensing school. “It was kismet! I did exactly that and have always felt so fortunate to have listened to them,” Potvin shares. Her dedication to helping clients realize their real estate dreams has driven her success as a top Realtor in the area.

Potvin’s commitment to her clients is evident in her around-the-clock availability and exceptional communication skills. She believes that being accessible and providing continuous support during major life events is crucial. “I am available to my clients 24/7, or anytime they need me. It instills comfort during a major life event,” she explains. This unwavering dedication has earned her the trust and loyalty of her clients, setting her apart from other Realtor agents in Los Altos, CA.

As a top real estate selling agent in Los Altos, CA, market preparation is a key aspect of Potvin’s service. She uses her extensive network of subcontractors to update homes, making them more appealing to today’s buyers. “I know what today’s buyers are looking for and can transform a slightly dated or even greatly outdated home into a much more marketable home that will receive top dollar,” Potvin states. Her strategic approach ensures that sellers achieve the best possible outcome in the market.

For those looking to navigate the Los Altos real estate market with confidence, Shelly Potvin offers unparalleled service and expertise. Visit http://www.shellypotvin.com/ to learn more about her services and to begin your real estate journey today.

Media Contact
Company Name: Shelly Potvin | Real Estate Agent in Los Altos CA
Contact Person: Shelly Potvin
Email: Send Email
Phone: +1 650-303-7501
Address:467 1st St
City: Los Altos
State: California 94022
Country: United States
Website: http://www.shellypotvin.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Best Real Estate Agent in Los Altos, CA, Leverages Local Expertise for Strategic Home Sales

Nevada Canyon Presents A Unique Investment Opportunity To Capitalize On Gold’s Bull Run

For the investment ages, investors have been met with this phrase- “keep some capital exposure to gold.” That makes sense. Gold is a tangible store of value, an inflation hedge, and globally marketable. As important, it’s not prone to the wild swings in individual stocks, where single-day double-digit declines are an almost daily occurrence. To be fair in the comparison, gold prices nearly touched that undesired threshold on April 15th, 2013,dropping 9%, making it the second worst daily loss since 1983.

Still, while gold showed it’s susceptible to corrections, historically, it’s a safer place to park investment capital. To take advantage of that, most investors bypass hoarding physical gold, instead buying exposure to the shiny metal through ETFs, futures markets, or companies mining it. The latter presents investors with the best opportunity to earn significant ROI, primarily from investing in companies positioned to bring the precious metal above ground or sitting atop proven reserves.

Keep this in mind, though. Investing in the mining sector is far from risk-free or for the faint of heart. Moves higher and lower can be frequent, and it’s a fair bet that since the gold rush in the 1800s, many generations have created and lost significant wealth. For that reason, completing due diligence before selecting the investment vehicle is 100% advisable. After all, while that doesn’t eliminate risk, it can significantly mitigate it by revealing reasons that support an investment proposition. It also shows that while not all miners are created or operating on equal ground, there are standouts. The investor attention given to Nevada Canyon Gold Corp. (OTC: NGLD) indicates it may be one of them.

Supporting Its Stocks Bullish Activity

Trading at $3.37 with a market cap of roughly $87 million and its stock 51% higher from its Q2 low*, Nevada Canyon presents itself as a uniquely structured natural resource entity strategically focused on Nevada—a region historically recognized for gold exploration and mining due to its very mining-friendly regulatory framework. While Nevada Canyon Gold Corp. is classified as a “junior” miner in size, the company is and has been building and managing an impressive diversified portfolio of precious metal assets and properties through strategic partnerships with capable operators. Coupled with a management team with over 30 years of experience in Nevada and an innovative value-creation strategy, the attention earned may result from investors recognizing Nevada Canyon’s potential to capitalize on opportunities inherent to the gold rally that started in 2023 and brought gold prices to over $2421 last week. (*share price on July 16, 2024, 10:03 AM EST, Nasdaq. Price change from $2.20-$3.34, May 14, 2024-July 16, 2024)

While the tug of war between opinions of why the rally should or shouldn’t stay intact seems to always be raging, the daily price changes of gold should be less concerning to investors in a company like Nevada Canyon, noting its property, capital structure, and asset base presents a unique and lower-risk investment opportunity than many of its sector peers. That makeup is especially important in the face of junior mining market weakness, particularly in the Canadian markets. Moreover, it’s tangibly supported by recognizing Nevada Canyon’s investment and acquisitions in royalty-generating mineral proprieties.

While already boasting an impressive portfolio, the company is working to get larger through a strategy that leverages its well-capitalized position to purchase distressed property assets available below market value. Adding new assets would fortify already accruing revenue streams, which could fall faster toward the company’s bottom line resulting from its low overhead business model that leverages a distinctive combination of asset stability and growth potential through competitive advantages to maximize royalty and streaming business revenues. With plans to continue its mission of strategic acquisitions, the focus on building and managing a diversified, future cash-flowing portfolio may also provide an exit strategy via acquisition rather than investor ROI limited to only project cash flow.

Valuing The Tangibles

Still, while the former is specualtive, the latter supports the revenue-growth thesis. Nevada Canyon Gold Corp. already holds royalty and streaming potential on over 30,000 square miles in Nevada, the company has devised a strategy to monetize its assets more quickly. It intends to create royalty packages by acquiring royalty and revenue streams from smaller producing, pre-production, or pre-resource properties, and then selling these aggregated packages at higher valuations. This strategy is designed to maximize the value of individual properties through high-profit-margin aggregation while minimizing risk through diversification.

The company also stresses that the potential upside profit margins are much higher in pre-production royalties and streams by avoiding the high cost of putting mines into production. Its strategy relies heavily on letting other parties do the heavy lifting and expenditures. This, they say, creates short-term upside value in these assets while retaining a long-term royalty at a very low-cost basis, creating substantial upside value to its capital investments in the process.

Compelling Mineral and Metals Asset Portfolio

Spearheading that strategy are compelling portfolio assets. The Loman Project, a historic high-grade gold project located within the Walker Lane shear zone in Nevada, exemplifies Nevada Canyon’s approach to revenue generation. This project covers several past producing small-scale high-grade gold and copper mines. Historical sampling has revealed significant potential for new discoveries of gold mineralization, which is unsurprising given the project’s location within a well-known gold belt with a long history of substantial gold production.

Another notable property is the Swales Property, which consists of 40 unpatented mining claims within the Carlin Trend, one of the world’s most historically proven mining districts. The property is near some of the largest gold mines in the U.S. and has significant exploration potential. The proximity to major producing mines suggests that Swales could host similar high-grade deposits, making it a prime target for further exploration and development.

The Belshazzar Project in Idaho’s Quartzburg mining district also supports Nevada Canyon’s strategic approach to monetizing its assets. This project, with historical high-grade gold production, remains underexplored, presenting opportunities for modern exploration techniques to unlock its potential. Advanced geophysical surveys and drilling programs could reveal new reserves.

Nevada Canyon’s portfolio of value drivers also includes royalty interests in properties like the Palmetto and Olinghouse projects. The Palmetto Project has a current initial NI 43-101 compliant mineral resource and significant exploration potential. The property has already demonstrated substantial gold and silver mineralization, and ongoing exploration efforts are expected to expand the list of known resources. Also notable is the Olinghouse Project location, which is within a well-established mining region and offers developers an established infrastructure with support services available to expedite development.

Nevada Canyon Gold Makes Its Case

Combining those assets with the ones expected to join the portfolio, the impressive increase in Nevada Canyon’s share price since June 15th looks justified from a sum of the company’s parts perspective. And with continued economic uncertainty and investors’ appetite for risk assets like stocks wavering, companies like Nevada Canyon Gold could benefit further in tandem with a gold market that’s shrugging off reports of taming inflationary pressures.

For Nevada Canyon Gold, being different may be its best attribute. Specifically, its unique approach to royalty and streaming, combined with its focus on acquiring more assets in Nevada’s prolific mining region, is a differentiation being viewed as an advantage. Based on intrinsic value alone, Nevada Canyon Gold presents a strong case for inclusion on the list of junior miners offering high-reward, lower-risk investment opportunities. Factoring in potential supports moving them higher up.

 

Disclaimers: This presentation has been created by Hawk Point Media Group, Llc. (HPM) and is responsible for the production and distribution of this content. This presentation should be considered and explicitly regarded as sponsored content. Hawk Point Media Group, LLC. has been compensated up to five thousand dollars via wire transfer from Sideways Frequency Llc. to research, compile, produce, and create digital content as part of a more extensive digital marketing program about the company. Accordingly, this content may be used and syndicated beyond the channels used by Hawk Point Media, Llc. This disclaimer and the link to the broader disclosures must be part of all reproductions of this content. The compensation received by HPM creates a conflict of interest because the content presented may only provide a favorable viewpoint of the company featured. The contributors do NOT buy and sell securities before and after any article, report, or publication. HPM holds ZERO shares and has never owned stock in Nevada Canyon Gold Corp. The information in this video, article, and related newsletters is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media Group, Llc. strongly urges you to conduct a complete and independent investigation of the respective companies and consider all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Never take opinions, articles presented, or content provided as the sole reason to invest in any featured company. Investors must always perform their own due diligence before investing in any publicly traded company and understand the risks involved, including losing their entire investment. 

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Nevada Canyon Presents A Unique Investment Opportunity To Capitalize On Gold\’s Bull Run

GNFEI Technology Co., Ltd Launches Next-Generation A3 DTG Printers and T-Shirt Printing Machines

GNFEI Technology Co., Ltd, a frontrunner in the printing solutions domain, is proud to announce the release of their innovative DTG Printers and T-shirt printers designed to elevate the standards of the printing industry.

GNFEI Technology Co., Ltd, a leading innovator in the printing industry, proudly presents its advanced lineup of printers. Among the highlights are the cutting-edge DTG Printer, the efficient t-shirt printer, and the versatile t-shirt printing machine, each designed to deliver high-quality results and unmatched performance.

t-shirt printer

GNFEI’s latest offering, the DTG Printer, is an A3-sized, full automatic control printer that supports both white and color ink printing simultaneously or at different times. With features like smart bidirectional printing, automatic nozzle checking, and a high-resolution EPSON 1390/1430/1500W print head, this printer ensures precise and efficient output for garment printing. With a print speed of approximately 173 seconds per A3 size photo image, this machine is an epitome of efficiency and quality. “Our DTG Printer embodies innovation and robustness, perfect for businesses seeking reliable printing solutions,” states William, spokesperson for GNFEI.

GNFEI’s t-shirt printer offers another excellent option with its high-speed EPSON XP600 head, delivering 100% faster performance compared to previous models. This model supports white and color ink printing simultaneously, making it ideal for bulk production. For those seeking a specialized solution for fabric printing, the t-shirt printer from GNFEI is a game-changer. The printer’s enhanced features allow for greater color accuracy and faster print times, making it an indispensable tool for those in the fashion and promotional merchandise industries. With the ability to handle various fabric types and thicknesses, this printer ensures that every t-shirt comes off the line looking its absolute best. This printer is designed to meet the demands of the textile industry, offering a seamless way to bring creative visions to life on t-shirts and other garments.

The t-shirt printing machine features advanced capabilities such as full automatic control, water cooling system, and smart ink management. Suitable for both flat and 3D surfaces, this machine’s versatility extends to various materials, offering high-resolution printing with precise positioning. It is a versatile device that can handle a variety of printing tasks with precision and ease, making it an indispensable tool for businesses looking to expand their printing capabilities.

GNFEI Technology Co., Ltd takes pride in its commitment to providing top-quality products and exceptional service. The company leverages cutting-edge technology and the expertise of skilled professionals to ensure that each printer meets the highest standards of performance and reliability. “Our dedication to innovation and customer satisfaction is reflected in every aspect of our product offerings,” William emphasizes.

About GNFEI Technology Co., Ltd

Welcome to GNFEI Technology Co., Ltd, a leading manufacturer and supplier of innovative printing solutions. We specialize in a wide range of printers, including UV printers, DTG printers, coffee latte printers, and more. Our state-of-the-art printers are designed to meet the needs of a variety of industries, from small businesses to large corporations.

Media Contact
Company Name: GNFEI Technology Co., Ltd
Contact Person: JOE LEE
Email: Send Email
State: Anhui
Country: China
Website: http://www.gnfei.com

CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent Milestones Can Transform This MedTech Company ($ENLV)

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) is a clinical-stage macrophage reprogramming immunotherapy company developing next-generation treatment options to combat osteoarthritis and inflammatory diseases. The company is advancing several clinical programs, evaluating Allocetra™, a universal, off-the-shelf cell therapy platform designed to restore immune balance, in treating knee osteoarthritis, basal thumb joint (first carpometacarpal joint) osteoarthritis sepsis as well as other inflammatory diseases. To learn more about this innovative company and how it plans to impact treatment markets, Hawk Point Media reached out to Enlivex Therapeutics CEO Oren Hershkovitz, Ph.D., to get a firsthand account of expectations for 2024. Here’s what Mr Hershkovitz said:

 

Q. Enlivex Therapeutics is in a biotech segment described as “next-gen” science. What does that mean, and how did you earn that descriptive?

A. It means we are doing things that are at the forefront of science that others don’t do. And we got here through innovation and perseverance. More specifically, Enlivex Therapeutics has evolved into a clinical-stage company that is advancing one of the most innovative and potentially effective immunotherapy technologies known: macrophage reprogramming.

Q. What is a macrophage?

A. Macrophages are a type of white blood cell that plays a critical role in the human immune system, particularly in facilitating vital functions such as engulfing and digesting microorganisms. These macrophages are crucial to overall health because they clear out debris and dead cells and stimulate other cells to get involved in immune function.

Q. These need reprogramming?

A. Yes, in many cases. While the human body is a marvel, it sometimes needs help to treat diseases and other medical conditions. Actually, in many diseases, macrophages drive an immune inflammatory acute or chronic state that is harmful. Therefore, reprogramming critical immune defenses and returning them to do their jobs more effectively is essential to treat the disease We are providing that ability by advancing what we believe will be a breakthrough treatment to the sector with Allocetra™, an immunotherapy aimed at reprogramming macrophages to treat various diseases. We are on the path to proving that after publishing positive interim results from a Phase I/II trial for knee osteoarthritis and dosing the first patient in a Phase I/II trial for thumb osteoarthritis..

Q. Why did you target these conditions?

A. For several reasons. Firstly, immunotherapy treatment for patients with those diseases is critically needed, noting that both conditions can be highly debilitating over time and are currently underserved and, in many cases, unmet medical needs. Second, before entering the clinic, our work showed that Allocetra™ could be an excellent treatment option based on its demonstrated ability to reprogram macrophages to treat inflammatory and autoimmune diseases. And thirdly, we can provide Allocetra™ as a universal, cost-effective off-the-shelf cell therapy with a simple manufacturing process. That third point is crucial because it will allow us to scale quickly, get effective treatment to patients, and begin generating ROI in as little as days after approval, not months. These are all multi-billion dollar markets with substantial unmet medical needs.

Keep in mind that we have already published positive interim data from a Phase I/II end-stage knee osteoarthritis (OA) trial and have announced that we have received regulatory authorization for the Phase I/II thumb osteoarthritis trial. So, we are working every day to reach those endpoints.

Q. What else is in the pipeline?

A. Quite a bit. We are advancing our Phase 2 clinical program, evaluating our treatments to combat organ failure associated with sepsis. And we are enrolling patients for our Phase 1/2 moderate knee, end-stage knee, and basal thumb osteoarthritis trials. We are also working vigorously to advance additional projects into clinical studies in other local chronic inflammatory diseases.

We have already published positive results in treating high-risk urosepsis, severe and critical COVID-19, and vanishing bone disease. Those publications highlight the role of apoptotic cells in immune homeostasis. That is important, especially related to sepsis and osteoarthritis, because there are currently no FDA/EMA-approved drugs to cure these diseases; current treatments only address complications, not the core immune response.

Allocetra™ is showing potential to address this unmet medical need, positioning it well to target a $33 billion global market for severe sepsis. Furthermore, because it is a cost-effective, novel therapeutic that can modulate and reprogram macrophages, we believe it can earn first-line designation to treat targeted conditions.

Q. You mentioned trials are underway. Can you provide more insight?

A. Yes, we have several ongoing trials. And the data is compelling. We just published interim results from end-stage osteoarthritis patients reporting substantial pain relief 3 months following AllocetraTM treatment. Results from our Phase I/II sepsis trial showed a potential indication of effect in the sepsis population of high-risk urinary tract infections. We have an ongoing placebo-controlled, randomized, double-blind trial in up to 160 patients with knee osteoarthritis and a phase I/II placebo-controlled, randomized, double-blind trial in up to 46 patients with basal thumb osteoarthritis. In our Phase I/II sepsis study, we saw a significant improvement in patient outcomes. Filling its role, Allocetra™ led to complete organ recovery in all treated patients by day 28. The results demonstrated statistically significant improvement in hospitalization duration and Sequential Organ Failure Assessment (SOFA) scores, which was coupled with a favorable safety profile in treated patients.

Q. You actually highlighted milestones in a recent CEO letter. Can you tell us more about that?

A. That letter highlighted achievements, including completing numerous pre-clinical studies, infusing Allocetra™ in over 100 patients and showing a favorable safety profile and potential efficacy, and provided an overview of results from our Phase 2 sepsis trial showing a potential effect and favorable safety profile, particularly in high-risk urinary tract infection sepsis patients.

Also highlighted was having cash resources on hand after completing our $15 million financing round to cover expected key trial milestones, including those related to our ongoing knee osteoarthritis and basal thumb trials. Milestones from those are anticipated in Q4 2024 as well as each quarter during 2025.

Q. You did announce interim results from the Knee Osteoarthritis trial, correct?

A. We did, and they were excellent, which is not going unnoticed. Remember, knee osteoarthritis is highly prevalent and disabling, with no approved treatments to slow or reverse the disease’s progression. Our trial design investigated Allocetra™ as a “last resort” alternative to knee replacement surgery. Interim results showed an average pain reduction in patients of 64%; 33% reported complete pain relief, and 89% avoided knee replacement surgery. Furthermore, no severe adverse events were reported, adding to the case for Allocetra™ to become a first-line, not a “last resort” treatment.

Q. It appears Enlivex is making operational and clinical strides across the board. How do you think 2024 and 2025 will play out?

A. We certainly have a filled agenda as we work toward delivering better treatment solutions for osteoarthritis and other inflammatory diseases. We have several ongoing trials, encouraging results from our lead product, Allocetra™, which could become a game-changer in treating degenerative joint diseases, and the capital to accelerate programs toward meeting endpoints, actually all the way to the end of 2026.

Let me end with this: Enlivex is not following the clinical herd. It is blazing a new trail for better treatment options with a drug that may provide relief for millions suffering from debilitating osteoarthritis conditions. If trial precedent holds, Enlivex could be a vital contributor to improving pain management and joint function and reducing the need for joint replacements. We are on the right track to deliver those results. In other words, 2024 can be a transformational year for this company.

 

End interview.

 

Pipeline:

Source: Enlivex Therapeutics

 

Read the June 2024 Enlivex Therapeutics company presentation by clicking HERE.

 

ABOUT ALLOCETRA™

Allocetra™ is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra™ has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening and life-debilitating clinical indications that are defined as “unmet medical needs.”

ABOUT BASAL THUMB OSTEOARTHRITIS

Osteoarthritis of the thumb is a chronic condition causing pain, stiffness and occasional clicking and swelling in the joint at the base of thumb (also known as the carpometacarpal or CMC joint). Simple daily tasks can become painful and difficult. The prevalence of thumb osteoarthritis increases substantially with age and is more common in postmenopausal woman. The prevalence of radiographic base thumb OA was reported to be 5.8% and 7.3%, for 50-year-old males and females, respectively, while the respective prevalence for 80-year-old male and female participants was reported as 33.1% and 39.0%1. The overall estimated symptomatic prevalence is up to 15% in adults over 30 years of age2. Osteoarthritis of the thumb is a degenerative and progressive condition, and over time, conservative treatments and anti-inflammatory medication to reduce pain and swelling start losing their effectiveness. Currently, there are no effective long-term treatments for this disease.

ABOUT ENLIVEX

Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http://www.enlivex.com.

Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.

 

Disclaimers: This presentation has been created by Hawk Point Media Group, Llc. (HPM) and is responsible for the production and distribution of this content. Hawk Point Media Group, LLC. has not been compensated to create this content. This content may be used and syndicated beyond the channels used by Hawk Point Media, Llc. This disclaimer must be part of all reproductions and re-publications . HPM holds ZERO shares and has never owned stock in Enlivex Therapeutics stock. The information in this video, article, and related newsletters is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media Group, Llc. strongly urges you to conduct a complete and independent investigation of the respective companies and consider all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Never take opinions, articles presented, or content provided as the sole reason to invest in any featured company. Investors must always perform their own due diligence before investing in any publicly traded company and understand the risks involved, including losing their entire investment.

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent Milestones Can Transform This MedTech Company ($ENLV)

Citius Pharmaceuticals (CTXR) Eyes Breakthrough with Late-Stage Drug Pipeline Poised for Regulatory Approval

On July 15, the firm EF Hutton initiated coverage on Citius with a Buy rating and price target of $6.00

Investing in the pharmaceutical industry carries inherent risks, especially when it involves pre-commercial entities where the outcome hinges on the unpredictable reactions of chemicals within the human body and the critical approval of regulators. However, a distinct stage in the regulatory process progressively “de-risks” these investments. As drugs transition through Phase I, Phase II, and Phase III to NDA/BLA submissions, their likelihood of reaching commercialization, generating revenue, and turning a profit increases substantially.

A revealing 2021 study examining development candidates from 2011–2020 found a mere 7.9% success rate from Phase I to regulatory approval, typically spanning over 10.5 years. Yet, the scenario brightens considerably at Phase III, with 57.8% of drugs moving on to NDA/BLA submissions and 90.6% of these gaining regulatory approval. This progression underscores why investors are increasingly drawn to late-stage companies with substantially de-risked assets.

Citius Pharmaceuticals: A Beacon of Hope in Late-Stage Pharma

Citius Pharmaceuticals (Nasdaq: CTXR) stands out as a prime example of a late-stage biopharmaceutical firm with a clear trajectory toward revolutionizing patient care. Recently, EF Hutton initiated coverage on Citius, assigning a Buy rating with an ambitious $6.00 price target, suggesting a potential surge of over 500% from the current price of the stock. 

Based in Cranford, New Jersey, Citius is poised to redefine the standard of care for patients with infections from Central Venous Catheters (CVCs). CVCs, essential in critical care, are used extensively across various patient demographics, including those in intensive care units, undergoing chemotherapy, or living with chronic conditions. These catheters, while vital, are susceptible to infections like CLABSI and CRBSI, which pose severe health risks and carry substantial financial burdens, with treatment costs soaring as high as $65,000.

Mino-Lok: A Game-Changing Therapy

Citius’s flagship product, Mino-Lok, an antibiotic lock solution acquired from the University of Texas MD Anderson Cancer Center, is designed to sterilize catheters without the need for removal. Invented by Dr. Issam Raad, Mino-Lok targets the biofilms that protect bacteria from antibiotics. The solution combines minocycline, EDTA, and ethanol to effectively disrupt these biofilms, offering a robust alternative to the standard, often ineffective “home brew” solutions.

Mino-Lok’s effectiveness was underscored by its “Fast Track” designation from the FDA, which expedites the review process. The solution has demonstrated its potential in a pivotal Phase III trial, achieving its primary endpoint with significant statistical significance and showing a favorable safety profile.

Expanding the Arsenal: LYMPHIR and Halo-Lido

Beyond Mino-Lok, Citius is developing LYMPHIR, a cancer drug targeting cutaneous T-cell lymphoma (CTCL). LYMPHIR, which has shown promising results in a Phase III trial, is awaiting FDA review. Additionally, Citius’s Halo-Lido, aimed at treating hemorrhoids, has shown positive outcomes in a Phase 2b trial and is moving towards further FDA discussions.

Looking Ahead

With multiple promising products in its pipeline and several near-term catalysts, Citius is strategically positioned for a potential breakout in the latter half of 2024. As the company approaches the breakeven point, with projected profits on the horizon in 2025, the commitment of Citius insiders and the optimistic assessments from analysts underscore a robust confidence in its future.

In conclusion, Citius Pharmaceuticals not only offers a compelling investment opportunity but also holds the promise of significantly enhancing the quality of life for patients through innovative treatments. With its strategic advancements and strong pipeline, Citius is well on its way to setting new standards in medical care and achieving substantial market success.

Other biotech stocks to keep on top of radar include Kazia Therapeutics (NASDAQ:KZIA), Biomarin Pharmaceuticals Inc. (NASDAQ: BMRN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), Incyte Corporation (NASDAQ: INCY), Exelixis, Inc. (NASDAQ: EXEL), Mimedx Group, Inc. (NASDAQ: MDXG), Genmab AS (NASDAQ: GMAB), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Bio-Techne Corp (NASDAQ: TECH), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ).

Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of CTXR or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at https://investorbrandmedia.com/disclaimer/. InvestorBrandMedia.com has been compensated five hundred dollars by a 3rd party Momentum Media LLC  for content distribution services on CTXR for July 17th, 2025. InvestorBrandMedia.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future results.InvestorBrandMedia.com does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in trading.InvestorBrandMedia.com is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by InvestorBrandMedia.com or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. InvestorBrandMedia.com is not a fiduciary by virtue of any person’s use of or access to this content. 

Source: 

https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf

https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/nda-and-bla-approvals

https://www.investing.com/news/company-news/ef-hutton-sets-citius-pharmaceuticals-stock-target-with-buy-rating-93CH-3519377

Media Contact
Company Name: Investor Brand Media
Contact Person: Ash K
Email: investorbrandmedia@gmail.com
Country: United States
Website: https://investorbrandmedia.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Citius Pharmaceuticals (CTXR) Eyes Breakthrough with Late-Stage Drug Pipeline Poised for Regulatory Approval

Myrtle Beach Asphalt Paving Explains Key Considerations for Successful Asphalt Paving

Myrtle Beach Asphalt Paving Explains Key Considerations for Successful Asphalt Paving
Myrtle Beach Asphalt Paving is a top-rated asphalt paving company. In a recent update, the company explained key considerations for successful asphalt paving.

Myrtle Beach, SC – In a website post, Myrtle Beach Asphalt Paving explained key considerations for successful asphalt paving.

The experts affirmed that selecting the right materials is essential for successful asphalt paving Myrtle Beach. The type and quality of asphalt used directly impact the longevity and performance of the paved surface. Factors such as climate and expected traffic loads dictate the appropriate mix design, ensuring durability against weather elements and heavy usage.

The paving contractor Myrtle Beach noted that proper preparation of the base is critical. Before laying down asphalt, ensuring a stable and well-compacted base is vital. This preparation phase not only enhances the pavement’s structural integrity but also prevents issues like cracking and uneven settling over time. Adequate drainage planning is also crucial during this stage to mitigate water damage and prolong the pavement’s lifespan.

Lastly, the asphalt contractor Myrtle Beach said that effective maintenance planning is key to preserving the integrity of asphalt surfaces. Routine inspections and timely repairs can prevent minor issues from escalating. Implementing a proactive maintenance schedule, including seal coating and crack sealing, helps extend the pavement’s life and maintain its appearance and functionality.

About Myrtle Beach Asphalt Paving 

Myrtle Beach Asphalt Paving is a premier asphalt paving company. The firm employs highly skilled professionals who blend their expertise with a strong commitment to delivering exceptional service. They offer complete asphalt paving services, guiding clients from the first consultation phase to the successful completion of projects. Whether the task involves paving driveways, parking lots, or large-scale commercial areas, Myrtle Beach Asphalt Paving consistently aims to surpass client expectations through effective project management and scrupulous attention to every detail.

Media Contact
Company Name: Myrtle Beach Paving
Contact Person: Jason Brown
Email: Send Email
Phone: (866) 544-1867
Address:1484 Linen Dr STE B
City: Myrtle Beach
State: SC
Country: United States
Website: https://myrtlebeachasphaltpaving.com/

Mid Atlantic Fence Supply Explains Why Vinyl Fence Materials are a Superior Choice

Mid Atlantic Fence Supply is a top-rated vinyl fencing solutions company. In a recent update, the company explained why vinyl fence materials are a superior choice.

Chesapeake, VA – In a website post, Mid Atlantic Fence Supply explained why vinyl fence materials are a superior choice.

The technicians asserted that vinyl fence materials Chesapeake are known for their durability and longevity, making them a practical choice for any outdoor environment. They are intended to withstand adverse weather conditions, including heavy rain, strong winds, and prolonged exposure to sunlight, without fading or warping. This durability ensures that vinyl fences require minimal upkeep, saving homeowners time and money on maintenance costs. 

The professionals said that vinyl fencing materials Chesapeake are renowned for their ease of installation. Unlike traditional fencing materials that often require specialized tools and skills, vinyl fences can be installed quickly and efficiently. Many vinyl fence panels come pre-assembled, reducing installation time and labor costs. Homeowners can choose between various installation methods, including DIY options or professional installation services, depending on their preferences and skill levels. 

Lastly, the experts noted that vinyl fence materials are considered high quality fencing materials Chesapeake due to their resistance to pests and rot. Unlike wood fences that are susceptible to insect infestations and decay over time, vinyl fences are impervious to termites, ants, and moisture damage. This resistance ensures that vinyl fences maintain their structural integrity and appearance for years, giving homeowners confidence that their property is secure and protected. 

About Mid Atlantic Fence Supply 

Mid Atlantic Fence Supply is a premier vinyl fencing solutions company. The facility offers a diverse range of vinyl fencing products designed to improve the aesthetic appeal and functionality of any outdoor space. Their vinyl fencing materials are crafted by employing advanced manufacturing techniques to guarantee long-lasting quality and performance Mid Atlantic Fence Supply offers innovative vinyl fencing solutions tailored to meet each client’s needs.

Media Contact
Company Name: Mid Atlantic Fence Supply
Contact Person: Michael Keesee
Email: Send Email
Phone: (757) 547-0044
Address:812 Tluchak Ln #100
City: Chesapeake
State: VA
Country: United States
Website: https://www.midatlanticfencesupply.com/